BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/22/2023 3:31:13 AM | Browse: 131 | Download: 457
 |
Received |
|
2023-06-01 08:06 |
|
Peer-Review Started |
|
2023-06-01 08:07 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-08-16 06:11 |
|
Revised |
|
2023-09-05 03:05 |
|
Second Decision |
|
2023-11-13 00:55 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-11-17 07:16 |
|
Articles in Press |
|
2023-11-17 07:16 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-11-06 17:20 |
|
Typeset the Manuscript |
|
2023-12-18 09:09 |
|
Publish the Manuscript Online |
|
2023-12-22 03:31 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ning Wang, Fei-Li Chen, Lu Pan, Yan Teng, Xiao-Juan Wei, Han-Guo Guo, Xin-Miao Jiang, Ling Huang, Si-Chu Liu, Zhan-Li Liang and Wen-Yu Li |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wen-Yu Li, Doctor, Chief Doctor, School of Medicine, South China University of Technology, No. 123 Huifu West Road, Guangdong 510006, Guangdong Province, China. lwy80411@163.com |
| Key Words |
Zanubrutinib; High-dose methotrexate; Primary central nervous system lymphoma; Liquid biopsy; Circulating tumor DNA |
| Core Tip |
Zanubrutinib combined with high-dose methotrexate provided a marked clinical response and tolerance in newly diagnosed primary central nervous system lymphoma patients. Additionally, the detection of circulating tumor DNA in cerebrospinal fluid played a significant part in disease surveillance and treatment response monitoring. However, given the small sample size and retrospective nature of this study, further research is required to validate our findings. |
| Publish Date |
2023-12-22 03:31 |
| Citation |
Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619 |
| URL |
https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v14.i12.606 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
